Sichenzia Ross Ference Carmel LLP Represents Lexaria Bioscience Corp. in a $3.6 Million Registered Direct Offering  

Press Release – New York, NY – February 16, 2024 – Sichenzia Ross Ference Carmel LLP announced today that it represented Lexaria Bioscience Corp. (the “Company”), (NASDAQ: LEXX), a global innovator in drug delivery platforms, in a $3.6 million registered direct offering priced at-the-market under Nasdaq rules. The deal consists of 1,558,443 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $2.31 per share (or per common stock equivalent in lieu thereof). In a concurrent private placement, the Company issued unregistered warrants to purchase up to 1,558,443 shares of common stock at an exercise price of $2.185 per share that are immediately exercisable upon issuance and will expire five years following the date of issuance. The gross proceeds to the Company for the offering were approximately $3.6 million. 

The Sichenzia Ross Ference Carmel LLP team was led by partners Gregory Sichenzia and Avital Perlman and associate Christian Lichtenberger.